ALL Search
collection
Collection Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making
J. Stratil
2020-02-12T04:43:55Z
Thumbnail
Additional file 5 of Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making
J. Stratil
2020-02-12T04:43:54Z
dataset
Additional file 4 of Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making
J. Stratil
2020-02-12T04:43:53Z
dataset
Additional file 3 of Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making
J. Stratil
2020-02-12T04:43:52Z
Thumbnail
Additional file 2 of Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making
J. Stratil
2020-02-12T04:43:50Z
Thumbnail
Additional file 1 of Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making
J. Stratil
2020-02-12T04:43:49Z
collection
Collection Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
Sarah Dewilde
2020-02-11T05:31:45Z
Thumbnail
Additional file 6 of Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
Sarah Dewilde
2020-02-11T05:31:44Z
Thumbnail
Additional file 5 of Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
Sarah Dewilde
2020-02-11T05:31:43Z
Thumbnail
Additional file 4 of Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
Sarah Dewilde
2020-02-11T05:31:42Z